Atherosclerotic renal artery stenosis is prevalent in cardiorenal patients but not associated with left ventricular function and myocardial fibrosis as assessed by cardiac magnetic resonance imaging

BMC Cardiovascular Disorders

Carlo AJM Gaillard⁵  Branko Braam⁸  Pieter AFM Doevendans⁶  Louis Meiss⁷  Hans L Hillege¹  Yves GCJ America²  Maarten J Cramer⁶  Jan JJ de Vries⁷  Birgitta K Velthuis³  Karien van der Putten⁴  Mireille E Emans⁴ 

[1] Department of Cardiology, UMC Groningen, University of Groningen, UMC Groningen, the Netherlands;Department of Cardiology, Rijnstate Hospital, Arnhem, the Netherlands;Department of Radiology, UMC Utrecht, the Netherlands;Department of Internal Medicine, Meander MC Amersfoort, the Netherlands;Department of Nephrology, VU University Medical Centre, Amsterdam, the Netherlands;Department of Cardiology, UMC Utrecht, the Netherlands;Department of Radiology, Meander MC Amersfoort, the Netherlands;Department of medicine, division of Nephrology and Immunology and department of Physiology, University of Alberta, Edmonton, Canada

关键词: Late gadolinium enhancement;    Magnetic resonance imaging;    Atherosclerotic renal artery stenosis;    Cardiorenal failure;   

Others  :  1084395
DOI  :  10.1186/1471-2261-12-76

 received in 2012-04-23, accepted in 2012-09-04,  发布年份 2012

【 摘 要 】

Background

Atherosclerotic renal artery stenosis (ARAS) is common in cardiovascular diseases and associated with hypertension, renal dysfunction and/or heart failure. There is a paucity of data about the prevalence and the role of ARAS in the pathophysiology of combined chronic heart failure (CHF) and chronic kidney disease (CKD). We investigated the prevalence in patients with combined CHF/CKD and its association with renal function, cardiac dysfunction and the presence and extent of myocardial fibrosis.

Methods

The EPOCARES study (ClinTrialsNCT00356733) investigates the role of erythropoietin in anaemic patients with combined CHF/CKD. Eligible subjects underwent combined cardiac magnetic resonance imaging (cMRI), including late gadolinium enhancement, with magnetic resonance angiography of the renal arteries (MRA).

Results

MR study was performed in 37 patients (median age 74 years, eGFR 37.4 ± 15.6 ml/min, left ventricular ejection fraction (LVEF) 43.3 ± 11.2%), of which 21 (56.8%) had ARAS (defined as stenosis >50%). Of these 21 subjects, 8 (21.6%) had more severe ARAS >70% and 8 (21.6%) had a bilateral ARAS >50% (or previous bilateral PTA). There were no differences in age, NT-proBNP levels and medication profile between patients with ARAS versus those without. Renal function declined with the severity of ARAS (p = 0.03), although this was not significantly different between patients with ARAS versus those without. Diabetes mellitus was more prevalent in patients without ARAS (56.3%) against those with ARAS (23.8%) (p = 0.04). The presence and extent of late gadolinium enhancement, depicting myocardial fibrosis, did not differ (p = 0.80), nor did end diastolic volume (p = 0.60), left ventricular mass index (p = 0.11) or LVEF (p = 0.15). Neither was there a difference in the presence of an ischemic pattern of late enhancement in patients with ARAS versus those without.

Conclusions

ARAS is prevalent in combined CHF/CKD and its severity is associated with a decline in renal function. However, its presence does not correlate with a worse LVEF, a higher left ventricular mass or with the presence and extent of myocardial fibrosis. Further research is required for the role of ARAS in the pathophysiology of combined chronic heart and renal failure.

【 授权许可】

   
2012 Emans et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Bongartz LG: The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 2004, 26(1):11-17.
• [2]Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL: Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007, 13(8):599-608.
• [3]McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW: Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109(8):1004-1009.
• [4]Safian RD, Textor SC: Renal-artery stenosis. N Engl J Med 2001, 344(6):431-442.
• [5]Burket MW, Cooper CJ, Kennedy DJ, Brewster PS, Ansel GM, Moore JA, Venkatesan J, Henrich WL: Renal artery angioplasty and stent placement: predictors of a favorable outcome. Am Heart J 2000, 139(1 Pt 1):64-71.
• [6]Shetty R, Amin MS, Jovin IS: Atherosclerotic renal artery stenosis: current therapy and future developments. Am Heart J 2009, 158(2):154-162.
• [7]de Mast Q, Beutler JJ: The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens 2009, 27(7):1333-1340.
• [8]Mui KW: Incidental Renal Artery Stenosis Is an Independent Predictor of Mortality in Patients with Peripheral Vascular Disease. J Am Soc Nephrol 2006, 17(7):2069-2074.
• [9]de Silva R, Loh H, Rigby AS, Nikitin NP, Witte KK, Goode K, Bhandari S, Nicholson A, Clark AL, Cleland JG: Epidemiology, associated factors, and prognostic outcomes of renal artery stenosis in chronic heart failure assessed by magnetic resonance angiography. Am J Cardiol 2007, 100(2):273-279.
• [10]Kane GC, Xu N, Mistrik E, Roubicek T, Stanson AW, Garovic VD: Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2010, 25(3):813-820.
• [11]Cohen M, Andrespascua J, Garciaben M, Rojasmatas C, Gabay J, Berrocal D, Tan W, Stouffer G, Montoya M, Fernandez A: A simple prediction rule for significant renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 2005, 150(6):1204-1211.
• [12]Wright JR: Left Ventricular Morphology and Function in Patients with Atherosclerotic Renovascular Disease. J Am Soc Nephrol 2005, 16(9):2746-2753.
• [13]van der Putten K, Jie KE, Emans ME, Verhaar MC, Joles JA, Cramer MJ, Velthuis BK, Meiss L, Kraaijenhagen RJ, Doevendans PA, et al.: Erythropoietin treatment in patients with combined heart and renal failure: objectives and design of the EPOCARES study. J Nephrol 2010, 23(4):363-368.
• [14]Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, et al.: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112(12):e154-e235.
• [15]Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, et al.: How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28(20):2539-2550.
• [16]White JA, Patel MR: The role of cardiovascular MRI in heart failure and the cardiomyopathies. Magn Reson Imaging Clin N Am 2007, 15(4)):541-564. vi
• [17]Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS: Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart, A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging 2002, 18(1):539-542.
• [18]Roes SD, Kelle S, Kaandorp TA, Kokocinski T, Poldermans D, Lamb HJ, Boersma E, van der Wall EE, Fleck E, de Roos A, et al.: Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 2007, 100(6):930-936.
• [19]Bax L, Woittiez AJ, Kouwenberg HJ, Mali WP, Buskens E, Beek FJ, Braam B, Huysmans FT, Schultze Kool LJ, Rutten MJ, et al.: Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009, 150(12)):840-848. W150-841
• [20]MacDowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K: Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998, 352(9121):13-16.
• [21]Maeder MT, Kaye DM: Heart Failure With Normal Left Ventricular Ejection Fraction. J Am Coll Cardiol 2009, 53(11):905-918.
• [22]van Kraaij DJ, van Pol PE, Ruiters AW, de Swart JB, Lips DJ, Lencer N, Doevendans PA: Diagnosing diastolic heart failure. Eur J Heart Fail 2002, 4(4):419-430.
• [23]Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, et al.: ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations. J Vasc Interv Radiol 2006, 17(9)):1383-1397. quiz 1398
• [24]Kumbhani DJ, Bavry AA, Harvey JE, de Souza R, Scarpioni R, Bhatt DL, Kapadia SR: Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J 2011, 161(3)):622-630. e621
• [25]Kane GC, Xu N, Mistrik E, Roubicek T, Stanson AW, Garovic VD: Renal artery revascularization improves heart failure control in patients with atherosclerotic renal artery stenosis. Nephrol Dial Transplant 2009, 25(3):813-820.
• [26]Kalra PA, Guo H, Kausz AT, Gilbertson DT, Liu J, Chen SC, Ishani A, Collins AJ, Foley RN: Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005, 68(1):293-301.
• [27]Sawicki PT, Kaiser S, Heinemann L, Frenzel H, Berger M: Prevalence of renal artery stenosis in diabetes mellitus–an autopsy study. J Intern Med 1991, 229(6):489-492.
• [28]Iglesias JI, Hamburger RJ, Feldman L, Kaufman JS: The natural history of incidental renal artery stenosis in patients with aortoiliac vascular disease. Am J Med 2000, 109(8):642-647.
• [29]Ozkan U, Oguzkurt L, et al.: The prevalence and clinical predictors of incidental atherosclerotic renal artery stenosis. Eur J Radiol 2009, 69(3):550-554.
• [30]Eriksson P, Mohammed AA, De Geer J, Kihlberg J, Persson A, Granerus G, Nystrom F, Smedby O: Non-invasive investigations of potential renal artery stenosis in renal insufficiency. Nephrol Dial Transplant 2010, 25(11):3607-3614.
• [31]van Jaarsveld BC, Krijnen P, Pieterman H, Derkx FH, Deinum J, Postma CT, Dees A, Woittiez AJ, Bartelink AK, Veld AJ Mi't, et al.: The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000, 342(14)):1007-1014.
• [32]Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, Loose H, Main J, Padfield P, Russell IT, et al.: Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis, Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998, 12(5):329-335.
• [33]Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011, 32(22):2851-2906.
• [34]Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, et al.: Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J 2006, 152(1):59-66.
• [35]Kadziela J, Witkowski A, Januszewicz A, Cedro K, Michalowska I, Januszewicz M, Kabat M, Prejbisz A, Kalinczuk L, Zielen P, et al.: Assessment of renal artery stenosis using both resting pressures ratio and fractional flow reserve: relationship to angiography and ultrasonography. Blood Press 2011, 20(4):211-217.